On the other hand, it has been reported that in NSCLC, patients with both TP53 and ATM mutations showed a higher response to treatment for ICIs due to having a significantly higher tumor mutation burden in comparison to groups with either mutation alone or without mutation [34]. This evidence concerns the gene ATM and non-small cell lung carcinoma.